



AgomAb Therapeutics Closes Series A Extension Round with Additional Funding from Andera Partners

Ghent, Belgium, 10 October 2019 – AgomAb Therapeutics N.V. ('AgomAb'), a privately held Belgian biotherapeutics company developing agonistic antibodies for the regeneration of damaged tissues, announces today that it has secured additional financing in an extension to its Series A financing round from new investor Andera Partners. The new proceeds add to the €21 million Series A financing round announced in April of this year.

The Company's International syndicate of experienced life sciences venture capital investors now include V-Bio Ventures (Belgium) and Advent France Biotechnology (France), Boehringer Ingelheim Venture Fund (Germany), Omnes (France), Pontifax (Israel), Andera Partners (France) and private investors.

- ENDS -

At AgomAb

Tim Knotnerus, CEO
tim.knotnerus@agomab.com

For media enquiries

Instinctif Partners (UK and RoW)
Sue Charles/Ashley Tapp
+44 (0)20 7866 7923
AgomAb@instinctif.com

Notes to Editors

About AgomAb Therapeutics N.V.

AgomAb is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. Based in Ghent Belgium, it is backed by an International syndicate of experienced life sciences venture capital investors. Find out more about us online at www.agomab.com.

About Andera Partners

Created in 2001 as part of the Edmond de Rothschild Group, Andera Partners is now an independent leading private equity investor present internationally. The Firm manages nearly €2.3 billion in investments in life sciences (BioDiscovery), growth capital and OBO (Winch Capital for midcap and Cabestan Capital for small-cap) and sponsorless mezzanine debt (ActoMezz). 100% owned by its teams, its core values focus on partnering with entrepreneurs and respect for its business partners. The company is also a signatory to the United Nations Principles for Responsible Investment (UNPRI), which encourage the adoption of best environmental, social and governance (ESG) practices.

Based in Paris, Andera Partners is an AMF-accredited asset management company and has 64 employees, 44 of whom are investment professionals. The performance of the firm's funds, its management structure and the range of its services have identified Andera Partners as a leader in its markets.

Andera's Life Sciences team of 12 professionals brings together deep experience both in the Life Science industry and in private equity and venture capital. The team has raised more than €800 million through its BioDiscovery franchise and is currently investing out of its €345 million BioDiscovery 5 fund.

For more information, please visit: www.anderapartners.com